Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA)

Melanoma Clinical Trial

— CAPRA  

Official title:

Phase I Study of Intratumoral CAVATAK® (Coxsackievirus A21) and Pembrolizumab in Subjects With Advanced Melanoma (VLA-011 CAPRA)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02565992
• Other study ID #: V937-007
• Secondary ID: VLA-011
• Status: Completed
• Phase: Phase 1
• Start date: December 17, 2015
• Est. completion date: November 4, 2019

Study information

• Verified date: January 2023
• Source: Viralytics
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study will employ a phase Ib design using the established dose of CAVATAK with pembrolizumab in subjects with advanced melanoma for whom pembrolizumab would be considered standard of care. Our hypothesis is that oncolysis of melanoma cells by CAVATAK will be important in amplifying the T-cell potentiating effects of pembrolizumab.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 36
• Est. completion date: November 4, 2019
• Est. primary completion date: November 4, 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Subjects with metastatic or unresectable stage IIIb/c of IV melanoma for whom treatment with pembrolizumab is indicated and who have at least one cutaneous, subcutaneous tumor or palpable lymph node amenable to intratumoral injection.

• At least one tumor must qualify to be an index lesion for modified WHO criteria.

• Subjects must have adequate hematologic, hepatic and renal function.

• ECOG performance status of 0 or 1.

• Anticipated lifespan greater than 12 weeks

Exclusion Criteria:

• Ocular primary tumors.

• Presence of any central nervous system tumor that has not been stable for at least 4 weeks off corticosteroids.

• Tumors lying in mucosal regions or close to an airway, major blood vessel or spinal cord.

• Subjects with active, known or suspected autoimmune or immunosuppressive disease.

• Subjects previously treated with CVA21.

• Subjects requiring systemic treatment with corticosteroids or other immunosuppressive medications within 14 days prior to the first treatment.

• Subject has received chemotherapy within the last 4 weeks prior to first treatment.

• Clinically significant cardiovascular disease.

• Females of childbearing potential must have negative serum or urine pregnancy test.

• Subjects requiring or using other investigational agents while on treatment in this trial.

• History of other malignancy within the last 3 years (with exceptions).

• Active infection requiring systemic therapy.

• Known history of HIV disease, active hepatitis B or hepatitis C.

• History or evidence of other clinically significant disorders that would pose a risk to subject safety.

• Inability to give informed consent and comply with the protocol.

Related Conditions & MeSH terms

• Melanoma

Intervention

Biological:
• CAVATAK
Maximum dose of CVA21 is 3 x 10E+08 TCID50 (about 4.5 x 10E+06 TCID50/kg for a 70-kg patient) by intratumoral administration.

Drug:
• Pembrolizumab
Intravenous pembrolizumab at 2 mg/kg solution.

Locations

Country	Name	City	State
United States	Gabrail Cancer Center Research	Canton	Ohio
United States	Rutgers Cancer Institute of New Jersey	New Brunswick	New Jersey
United States	John Wayne Cancer Institute	Santa Monica	California

Sponsors (1)

Lead Sponsor	Collaborator
Viralytics

Country where clinical trial is conducted

United States, 

References & Publications (1)

Silk AW, O'Day SJ, Kaufman HL, Bryan J, Norrell JT, Imbergamo C, Portal D, Zambrano-Acosta E, Palmeri M, Fein S, Wu C, Guerreiro L, Medina D, Bommareddy PK, Zloza A, Fox BA, Ballesteros-Merino C, Ren Y, Shafren D, Grose M, Vieth JA, Mehnert JM. A phase 1b — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The incidence of dose-limiting toxicities (DLT) of intravenous pembrolizumab in combination with intratumoral CAVATAK will be assessed using CTCAE v. 4.0.		Up to 2 years